Related Experiment Video
Updated: Apr 21, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial
Patrick Roth1, Michael Weller1
1Department of Neurology and Brain Tumor Center Zurich, University Hospital Zurich, Zurich, Switzerland (P.R., M.W.).
Abstract:
Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has therefore been regarded as a promising therapeutic strategy in glioblastoma for decades. However, although various pharmacological inhibitors and anti-EGFR antibodies are available, the antiglioma activity of these agents has been largely limited to preclinical models, whereas their administration to glioblastoma patients was characterized by lack of clinical benefit. Comprehensive efforts have been made within the last years to understand the underlying mechanisms that confer resistance to EGFR inhibition in glioma cells. The absence of well-known mutations that predict response to EGFR tyrosine kinase inhibitors (TKIs) in gliomas as well as the presence of redundant and alternative compensatory pathways are among the most important escape mechanisms that prevent potent antiglioma effects of EGFR-targeting drugs. Accordingly, an increasing number of in vitro and in vivo studies are aimed at overcoming this resistance by combinatorial approaches using anti-EGFR treatment together with one or more additional drugs. Novel insights into the molecular mechanisms mediating resistance to anti-EGFR treatment and promising combinatorial approaches may help to better define a future role for EGFR inhibition in the treatment of glioblastoma.
Insights
Targeting epidermal growth factor receptor (EGFR) in glioblastoma shows limited clinical benefit due to resistance. Combinatorial therapies are being explored to overcome these resistance mechanisms and improve treatment outcomes.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Epidermal growth factor receptor (EGFR) alterations are prevalent in glioblastomas, driving tumor growth and survival.
- EGFR signaling is crucial for glioblastoma cell proliferation, migration, and survival.
- EGFR-targeted therapies have shown promise in preclinical models but largely failed in clinical trials.
Purpose of the Study:
- To investigate the mechanisms of resistance to EGFR inhibition in glioblastoma.
- To explore novel combinatorial strategies to overcome EGFR-targeted therapy resistance.
- To define a potential future role for EGFR inhibition in glioblastoma treatment.
Main Methods:
- Review of existing literature on EGFR signaling and resistance mechanisms in glioblastoma.
- Analysis of preclinical and clinical studies on EGFR inhibitors and antibodies.
- Evaluation of emerging in vitro and in vivo studies on combinatorial approaches.
Main Results:
- Resistance to EGFR inhibition in gliomas is mediated by the absence of predictive mutations and the activation of compensatory pathways.
- Current EGFR-targeting agents demonstrate limited clinical efficacy in glioblastoma patients.
- Combinatorial strategies combining anti-EGFR treatment with other drugs are under investigation to enhance antiglioma activity.
Conclusions:
- Understanding resistance mechanisms is critical for developing effective EGFR-targeted therapies for glioblastoma.
- Combinatorial approaches hold promise for overcoming resistance and improving patient outcomes.
- Further research into novel therapeutic strategies is needed to leverage EGFR inhibition in glioblastoma treatment.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...